Ultime notizie per Aprea Therapeutics (NASDAQ:APRE) Azioni

Aprea Therapeutics

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Aprea Therapeutics Inc

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and Aprea Therap...

Analysts' Top Healthcare Picks: AstraZeneca (AZN), Aprea Therapeutics (APRE)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mirum Pharmaceuticals (MIRM – Research Report), Goss...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Gossamer Bio (GOSS) and Aprea Therapeutics (APRE)

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Aprea Therapeutics (APRE – Research Report), retaining the price target of $16.00....

Aprea Therapeutics' APR-1051: Poised for Leadership in WEE1 Inhibition with Promising Clinical and Market Potential

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pr...

Buy Rating Affirmed for Aprea Therapeutics on APR-1051's Promising Safety and Efficacy Profile

Maxim Group analyst Jason McCarthy has maintained their bullish stance on APRE stock, giving a Buy rating on June 24. Jason McCarthy has given his ...

Buy Rating on Aprea Therapeutics: Outshining Competitors with Selective and Potent WEE1 Inhibitor APR-1051

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aprea Therapeutics (APRE – Research Report) and TSca...

Analysts Are Bullish on These Healthcare Stocks: Aprea Therapeutics (APRE), TScan Therapeutics (TCRX)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Aprea Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/apre-stock-quote/"><strong>APRE</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Aprea Therapeutics reported earnings per share of -58 cents. This was above the analyst estimate for EPS of -64 cents.</li><li>The company reported revenue of $561,574.</li><li>This was 1,023.15% better than the analyst estimate for revenue of $50,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/apre-stock-earnings-aprea-therapeutics-for-q2-of-2024/">APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024

Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M

In a report released today, Robert Driscoll from Wedbush initiated coverage with a Buy rating on Aprea Therapeutics (APRE – Research Report) and a ...

Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) yesterday and set a price target of $16.0...

Comments

Aprea Therapeutics

Notizie

Ultime notizie per Aprea Therapeutics (NASDAQ:APRE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO